Low prevalence of reactive PPD prior to infliximab use: Comparative study on a population sample of Hospital Geral de Fortaleza

Revista Brasileira de Reumatologia

Volumn 51, Issue 1, 2011, Pages 40-52

  Callado, Maria Roseli Monteiro ^a   Lima, José Rubens Costa ^b   Nobre, Christiane Aguiar ^c   Vieira, Walber Pinto ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c HOSPITAL GERAL DE FORTALEZA   (Brazil)

^d Medical School of the UECE   (Brazil)

Author keywords

Biological therapy; Prevalence; Rheumatic diseases; Tuberculin test

Indexed keywords

INFLIXIMAB; TUBERCULIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BRAZIL; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG USE; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; POPULATION RESEARCH; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN INDURATION; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, GENERAL; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952948449     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Keane J. TNF-Blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44:714-720.
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatosis infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265.
3. Sociedade Brasileira de Reumatologia. Projeto Diretrizes da Associação Médica Brasileira e Conselho Federal de Medicina. Artrite Reumatóide: diagnóstico e tratamento. Disponível em: http:// www.projetodiretrizes.org.br/projeto_diretrizes/015.pdf. [Acessado em 23 de outubro de 2009].
4. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Disponível em: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr4906a1.htm. [Acessado em 23 de outubro de 2009].
5. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. Disponível em: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a4.htm. [Acessado em 23 de outubro de 2009].
6. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Guia para o diagnóstico, tratamento e prevenção da tuberculose. Disponível em: http://bvsms.saude.gov.br/bvs/ publicacoes/manual_tuberculose_2006.pdf. [Acessado em 26 de outubro de 2009].
7. Rangel-Frausto MS, Ponce-De-León-Rosales S, Martinez-Abaroa C, Haslov K. Tuberculosis and tuberculin quality: best intentions, misleading results. Infect Control Hosp Epidemiol 2001; 22(8):481-484.
8. Teixeira L, Maciel E, Dutra ME, Perkins MD, Johnson JL, do Valle Dettoni V. Simultaneous comparison of reactivity to purified protein derivative RT-23 and Tubersol in health care workers in Vitória, Brazil. Int J Tuberc Lung Dis 2000; 4(11):1074-1077.
9. Muñoz-Barret JM, Macías-Hernández AE, Hernández-Ramos I, Durán-Martínez E, Martínez-Magdaleno RM, Medina-Valdovinos H et al. Comparative tuberculin reactivity to two protein derivatives. Rev Invest Clin 1996; 48(5):377-381.
10. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15):1098-1104.
11. Criscione LG, Clair EW. Tumor necrosis factor-alfa antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002; 14:204-211.
12. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inibitors may predispose to significant increase in tuberculosis risk: a multi center active-surveillance report. Arthritis Rheum 2003; 48:2122-2127.
13. Ministério da Saúde - Programa Nacional de Controle da Tuberculose. Disponível em: http://portal.saude.gov.br/portal/saude/ visualizar_texto.cfm?idtxt=28055. [Acessado em 07 de outubro de 2009].
14. Filho AC, Kritski AL, Barreto AW, Lemos ACM, Netto AR, Guimarães CA et al. II Consenso Brasileiro de Tuberculose. Diretrizes Brasileiras para Tuberculose. J Bras Pneumol 2004; 30(1):1-55.
15. Façanha MC, Guerreiro MFF, Pinheiro AC, Costa Lima JR, Vale RLV, Teixeira GFD. Resgate de casos subnotifcados de tuberculose em Fortaleza-CE, 2000-2002. Bol Pneumol Sanit 2003; 11(2):13-16.
16. Marques CDL, Duarte ALBP, Lorena VMB, Souza JR, Souza W, Gomes YM et al. Resposta atenuada ao PPD no diagnóstico de infecção tuberculosa latente em pacientes com artrite reumatóide. Rev Bras Reumatol 2009; 49(2):121-125.
17. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009; 48(2):179-185.
18. Jain A, Dixit P. Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J Biosci 2008; 33(4):605-16.
19. Braga, JU. Equivalência das Reações cutâneas do PPD entre dois produtos comercializados no Brasil. Informe Epidemiológico do SUS 2000. Disponível em: http://bvsms.saude.gov.br/bvs/periodicos/ informe_epi_sus_v09_n3.pdf. [Acessado em 22 de outubro de 2009].
20. Teixeira L, Maciel E, Dutra ME, Perkins MD, Johnson JL, do Valle Dettoni V. Simultaneous comparison of reactivity to purified protein derivative RT-23 and Tubersol in health care workers in Vitória, Brazil. Int J Tuberc Lung Dis 2000; 4(11):1074-1077.
21. Muñoz-Barret JM, Macías-Hernández AE, Hernández-Ramos I, Durán-Martínez E, Martínez-Magdaleno RM, Medina-Valdovinos H et al. Comparative tuberculin reactivity to two protein derivatives. Rev Invest Clin 1996; 48(5):377-381.
22. Alonso Moreno FJ, García Bajo MC, Lougedo Calderón MJ, Comas Samper JM, García Palencia M, López de Castro F et al. Prevalence of tuberculosis infection among immigrants in the Toledo Health District, Spain. Rev Esp Salud Publica 2004; 78(5):593-600.
23. Ostrosky-Zeichner L, Rangel-Frausto MS, García-Romero E, Vázquez A, Ibarra MJ, Ponce de León-Rosales S. Tuberculosis in health personnel: importance of surveillance and control programs. Salud Publica Mex 2000; 42(1):48-52.
24. Kunins HV, Howard AA, Klein RS, Arnsten JH, Litwin AH, Schoenbaum EE et al. Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug users. J Gen Intern Med 2004; 19(10):1039-1044.
25. Linquist JA, Rosaia CM, Riemer B, Heckman K, Alvarez F. Tuberculosis exposure of patients and staff in an outpatient hemodialysis unit. Am J Infect Control 2002; 30(5):307-310.
26. Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients is the tuberculin test effective? Clin Nephrol 2003; 59(6):436-440.
27. Wauters A, Peetermans WE, Van den Brande P, De Moor B, Evenepoel P, Keuleers H et al. The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant 2004; 19(2):433-438.
28. Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 2004; 65(5):1826-1834.
29. Habesoglu MA, Torun D, Demiroglu YZ, Karatasli M, Sen N, Ermis H et al. Value of the tuberculin skin test in screening for tuberculosis in dialysis patients. Transplant Proc 2007; 39(4):883-886.
30. Laurindo IMM, Seiscento M, Bombardia S, Souza TNL, Eluf Neto J, Radu AS et al. Diagnosis of latent tuberculosis in rheumatoid arthritis (RA) patients: tuberculin test (PPD) assessment. EULAR 2004, Rheumatoid arthritis clinical aspects [THU0235]. Disponível em: http://www.abstracts2view.com/eular/sessionindex. php?session=2004374&day=2004. [Acessado em 27 de janeiro de 2010].
31. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNF-α Therapy. J Exp Med 2004; 200:277-285.
32. + T cells in the blood predicts the in vivo response to PPD. Tuberculosis 2006; 87(3):202-211.
33. Andrade TCB, Maia RM, Cosgrove C, Castelo Branco LRR. BCG Moreau Rio de Janeiro - An oral vaccine aginst tuberculosis - Review. Men Inst Oswaldo Cruz 2005; 100(5):459-465.
34. Maciel ELN, Viana MC, Zeitoune RCG, Ferreira I, Fregona G, Dietze R. Prevalence and incidence of Mycobacterium tuberculosis infection in nursing students in Vitória, Espírito Santo. Rev Soc Bras Med Trop 2005; 38(6):469-472.
35. Pilsczek FH, Kaufmann SHE. Prevalence and predictors of positive tuberculin skin test results in a research laboratory. Rev Soc Bras Med Trop 2008; 41(4):416-418.
36. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R et al. Attenuated response to purifed protein derivate in patients with rheumatoid artritis: study in a population with high prevalence of tuberculosis. Ann Rheum Dis 2005; 64:1360-1361.
37. Köker IH, Pamuk Ã-N, Karlikaya N, Tunçbilek N, Cakir N. A low prevalence of purifed protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT fndings. Clin Exp Rheumatol 2007; 25(1):54-59.
38. Maciel ELN, Meireles W, Silva AP, Fiorotti K, Dietze R. Transmissão nosocomial por Mycobacterium tuberculosis nos estudantes da área de saúde em uma região de alta incidência de tuberculose, Vitória, Estado do Espírito Santo. Rev Soc Bras Med Trop 2007; 40(4): 397-399.